Lundbeck has potential products in the pipeline for 2006  

2005.11.18
Danish pharmaceutical company Lundbeck has potential new products in the pipeline for 2006 and is preparing to launch Cipralex on the Japanese market

Danish pharmaceutical company Lundbeck has potential new products in the pipeline for 2006. Claus Bræstrup, senior executive at Lundbeck says one of the products has great potential: "It has a new mechanism. There are no other drugs under development anywhere in the world with that mechanism", he said in an interview with financial daily newspaper Børsen, but declined to disclose further information.

In the interview, the chief executive also said that Lundbeck is preparing to launch Cipralex on the Japanese market: "We are well advanced in bringing Cipralex to Japan and expect it will be around 2010", he said. Before launching the product, Lundbeck needs to conduct further clinical studies because Japanese authorities require that drugs are tested on Japanese patients, who have a different metabolism to Europeans.

Marketing in Japan will be carried out through one or several partnerships as well as through Lundbeck's own sales force. Japan is the world's next biggest market for medical products after the US.

Lundbeck is an international pharmaceutical company engaged in R&D, production, marketing and sales of drugs for the treatment of psychiatric and neurological disorders. In 2004, the company generated revenues of DKK 9.7 bn (USD 1.5 bn). Lundbeck is headquartered in Copenhagen and employs approx. 5,000 people.

Link > Lundbeck 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×